| Field | Specification |
|---|---|
| Target | |
| Alternative names | BMS-387032 |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C17H24N4O2S2 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
SNS-032, also known as BMS-387032, is a selective, potent inhibitor of three cyclin-dependent kinases: CDK9 (IC50 4 nM), CDK2 (38 nM) and CDK7 (62 nM). Antitumor activity has been reported for the compound[1]. It is supplied as a white to light yellow solid (C17H24N4O2S2, MW 380.53) at 99.91% purity.
Physical & Chemical Properties
| CAS Number | 345627-80-7 |
|---|---|
| Molecular Formula | C17H24N4O2S2 |
| Molecular Weight | 380.53 g/mol |
| Purity | 99.91% |
| Appearance | Solid |
| Color | White to light yellow |
| SMILES | CC(C)(C1=CN=C(CSC2=CN=C(NC(C3CCNCC3)=O)S2)O1)C |
| Target | CDK9, CDK2, CDK7, CDK9/cyclinT1 |
| Signaling Pathway | Cell Cycle/DNA Damage; Apoptosis |
| Solubility | In Vitro: DMSO: 50 mg/mL (131.40 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target[1]
|
CDK9 4 nM (IC50) |
CDK2 38 nM (IC50) |
CDK7 62 nM (IC50) |
CDK1 480 nM (IC50) |
CDK4 925 nM (IC50) |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 50 mg/mL (131.40 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.08 mg/mL (5.47 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 2.08 mg/mL (5.47 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Protocol 3
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 2.08 mg/mL (5.47 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 900 μL corn oil. |
Direct preparation of the working solution
These formulations are prepared directly, without a DMSO stock; use them promptly after preparation.
Protocol 4
| Composition | 50% PEG300 + 50% saline |
|---|---|
| Result | 10 mg/mL (26.28 mM); suspension; requires sonication |
Protocol 5
| Composition | 0.5% CMC-Na/saline water |
|---|---|
| Result | 25 mg/mL (65.70 mM); suspension; requires sonication |
Data provided by the manufacturer.
In Vitro
SNS-032 shows low sensitivity toward CDK1 and CDK4, with IC50 values of 480 nM and 925 nM, respectively. In vitro, SNS-032 effectively kills chronic lymphocytic leukemia cells irrespective of prognostic markers or prior treatment history. Relative to flavopiridol and roscovitine, SNS-032 shows greater potency at both inhibiting RNA synthesis and inducing apoptosis. SNS-032's activity is readily reversible: withdrawing SNS-032 reactivates RNA polymerase II, leading to resynthesis of Mcl-1 and cell survival[1]. SNS-032 inhibits formation of three dimensional capillary networks by endothelial cells. It completely blocks U87MG cell-mediated capillary formation by HUVECs. SNS-032 also significantly reduces VEGF production in both cell lines and prevents in vitro angiogenesis, an action attributable to blocking of VEGF. Preclinical studies have shown that SNS-032 induces cell cycle arrest and apoptosis across multiple cell lines[2]. It blocks the cell cycle via inhibition of CDKs 2 and 7, and blocks transcription via inhibition of CDKs 7 and 9. SNS-032's activity is unaffected by human serum[3]. SNS-032 causes a dose-dependent increase in annexin V staining and caspase-3 activation. At the molecular level, SNS-032 causes marked dephosphorylation of serine 2 and 5 of RNA polymerase (RNA Pol) II and inhibits the expression of CDK2 and CDK9, along with dephosphorylated CDK7[5].
In Vivo
In vivo, SNS-032 (15 mg/kg, i.p.) inhibits both xenografted BaF3-T674I cells and KBM5-T315I cells. It abrogates the growth of tumors transplanted in nude mice, with downregulation of T674I PDGFRα and T315I-Bcr-Abl[4].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Cell Assay[2]
Perform a Cell Titer-Glo (CTG) luminescent assay to measure the growth curves of HUVECs and U87MG cells. Seed U87MG cells and HUVECs (2×103 cells/well) in a 96-well microplate in a final volume of 100 μL. After 24 hours, treat cells with various doses of SNS-032 (0-0.5 μM) for 24, 48, or 72 hours. After completion of treatment, add 100 μL of CTG solution to each well and incubate for 20 minutes at room temperature in the dark. Transfer 50 μL of lysate to a 96-well white plate and measure luminescence with a POLARstar OPTIMA. Calculate percent cell growth by taking growth at the time of SNS-032 addition as 100%.
Animal Administration[4]
House nude nu/nu BALB/c mice in barrier facilities on a 12-hour light-dark cycle, with food and water available ad libitum. Inoculate a mixture of 1×107 BaF3-T674I cells with Matrigel, or KBM5-T315I cells (3×107), subcutaneously into the flanks of 4- to 6-week-old male nude mice. Measure tumors every other day using calipers. Calculate tumor volumes with the formula a2×b×0.4, where a is the smallest diameter and b is the diameter perpendicular to a. Four days after subcutaneous inoculation, once tumors are palpable (appr 100 mm3), randomize mice to receive vehicle (tissue culture medium containing DMSO 0.1% v/v) or SNS-032 (15 mg/kg injected intraperitoneally every 2 days) for about 2 weeks. Dissolve SNS-032 in tissue culture grade DMSO before dilution. Monitor the body weight, feeding behavior, and motor activity of each animal as indicators of general health. Euthanize the animals and immediately remove, weigh, store, and fix the tumor xenografts.
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
CDK9 recruits HUWE1 to degrade RARα and offers therapeutic opportunities for cutaneous T-cell lymphoma. Nat Commun 2024 Dec 5;15(1):10594. PMID: 39632829
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. Sci Transl Med 2018 Jul 18;10(450):eaaq1093.
Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. ACS Environ Au 2025 Aug 5;5(6):573-582. PMID: 41277996
Cardiolipin-mediated PPARγ S112 phosphorylation impairs IL-10 production and inflammation resolution during bacterial pneumonia. Cell Rep 2021 Feb 9;34(6):108736. PMID: 33567272
Discovery of dCDK9-202 as a Highly Potent and Selective PROTAC CDK9 Degrader with Strong In Vivo Antitumor Activity. J Med Chem 2025 Oct 23;68(20):21172-21186. PMID: 41066447
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. Anal Chem 2025 Jun 3;97(21):11099-11109. PMID: 40401576
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer. Int J Mol Sci 2022 May 13;23(10):5476. PMID: 35628286
Res Sq. 2025 Dec 18.
Research Square Preprint. 2024 May 2.
Patent. US20220175722A1.
